A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Acronyms RE-TUne
- Sponsors Marius Pharmaceuticals; SOV Therapeutics
- 06 Jul 2017 Status changed from not yet recruiting to recruiting.
- 23 Jun 2017 Status changed from planning to not yet recruiting.
- 24 Dec 2014 New trial record